Atopic Dermatitis Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 110+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Atopic Dermatitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atopic Dermatitis Market.

The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Atopic Dermatitis Pipeline Report: https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years.
• Atopic Dermatitis companies working in the treatment market are Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, RAPT Therapeutics, Inc., Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, GlaxoSmithKline, Almirall, S.A., Regeneron Pharmaceuticals, Amgen, Evelo Biosciences, Inc., Q32 Bio Inc., Amgen, Bristol-Myers Squibb, Akesobio Australia Pty Ltd, Incyte Corporation, AstraZeneca, AbbVie, and others are developing therapies for the Atopic Dermatitis treatment
• Emerging Atopic Dermatitis therapies in the different phases of clinical trials are- PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, GW842470X cream, LAS 41002, Dupilumab, RPT193, Apremilast, EDP1815, ADX-914, AMG 451, Rocatinlimab, BMS-986166, AK120, ruxolitinib cream, MEDI3506, Upadacitinib, Tofacitinib ointment, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.
• In November 2022, The first cohort of the Phase IIa clinical study for AB-101a, a topical treatment option for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old, has finished, according to an announcement from Alphyn Biologics. Patients without bacterial infections, which are occasionally linked to AD, were enrolled in the first cohort. Top-line outcomes should be visible in about eight weeks.
• In September 2022, In a Phase Ib trial to assess the safety and effectiveness of si-544 in people with mild to severe atopic dermatitis, including the length of clinical benefit, selectION stated that it has started dosing patients.
• In July 2022, According to 255 patients in its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis (AD), Connect Biopharma Holdings has received confirmation from the Centre for Drug Evaluation of the National Medical Products Administration (CDE) that it is permitted to conduct primary analysis of the trial. Therefore, earlier than anticipated, Connect Biopharma expects to announce the top-line results of this trial.
• In May 2022, In a single ascending dosage Phase I clinical trial investigating BBI-02 in healthy adult subjects and patients with atopic dermatitis, Brickell Biotech reported that the first individuals have been dosed. In patients with autoimmune and inflammatory illnesses, BBI-02, a potentially first-in-class, highly selective, orally accessible small molecule DYRK1A inhibitor, seeks to reestablish immunological balance by modifying innate and adaptive immune responses.
• In January 2021, "A Phase III, 4-Week, ParallelGroup, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis" is the name of the Phase III experiment that Arcutis Biotherapeutics started

Atopic Dermatitis Overview
Eczema, commonly known as atopic dermatitis (AD), is a chronic disorder that typically first manifests in early childhood but can happen at any age and remain for the rest of one's life. The term "dermatitis" Derm and itis are medical terms for skin irritation.

Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:
• PF 07242813: Pfizer
• KT-474: Kymera Therapeutics
• BEN2293: BenevolentAI
• MEDI3506: AstraZeneca
• Q301: Qurient
• SB011: Sterna Biologicals
• Tradipitant: Vanda Pharmaceuticals
• Roflumilast: Arcutis Biotherapeutics
• GW842470X cream: GlaxoSmithKline
• LAS 41002: Almirall, S.A.
• Dupilumab: Regeneron Pharmaceuticals
• RPT193: RAPT Therapeutics, Inc.
• Apremilast: Amgen
• EDP1815: Evelo Biosciences, Inc.
• ADX-914: Q32 Bio Inc.
• AMG 451: Amgen
• Rocatinlimab: Amgen
• BMS-986166: Bristol-Myers Squibb
• AK120: Akesobio Australia Pty Ltd
• ruxolitinib cream: Incyte Corporation
• MEDI3506: AstraZeneca
• Upadacitinib: AbbVie
• Tofacitinib ointment: Pfizer

Atopic Dermatitis Route of Administration
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Atopic Dermatitis Molecule Type
Atopic Dermatitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Atopic Dermatitis Pipeline Therapeutics Assessment
• Atopic Dermatitis Assessment by Product Type
• Atopic Dermatitis By Stage and Product Type
• Atopic Dermatitis Assessment by Route of Administration
• Atopic Dermatitis By Stage and Route of Administration
• Atopic Dermatitis Assessment by Molecule Type
• Atopic Dermatitis by Stage and Molecule Type

DelveInsight's Atopic Dermatitis Report covers around 110+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Atopic Dermatitis product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies at:

Some of the key companies in the Atopic Dermatitis Therapeutics Market include:
Key companies developing therapies for Atopic Dermatitis are - Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, Evommune, Inc., Fresh Tracks Therapeutics, Biosion, Chia Tai Tianqing Pharmaceutical, Reistone Biopharma Company Limited, JW Pharmaceutical, Oneness Biotech, Alphyn Biologics, selectION, UNION Therapeutics, Ichnos Sciences, and others.

Atopic Dermatitis Pipeline Analysis:
The Atopic Dermatitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
• Atopic Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies-
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atopic Dermatitis Pipeline Market Drivers
• Rising prevalence of AD, escalating expenditure on health care, potential Emerging Therapies are some of the important factors that are fueling the Atopic Dermatitis Market.

Atopic Dermatitis Pipeline Market Barriers
• However, over-the-counter medications, outdated treatment recommendations, poor prognosis and treatment adherence and other factors are creating obstacles in the Atopic Dermatitis Market growth.

Scope of Atopic Dermatitis Pipeline Drug Insight
• Coverage: Global
• Key Atopic Dermatitis Companies: Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, RAPT Therapeutics, Inc., Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, GlaxoSmithKline, Almirall, S.A., Regeneron Pharmaceuticals, Amgen, Evelo Biosciences, Inc., Q32 Bio Inc., Amgen, Bristol-Myers Squibb, Akesobio Australia Pty Ltd, Incyte Corporation, AstraZeneca, AbbVie, and others
• Key Atopic Dermatitis Therapies: PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, GW842470X cream, LAS 41002, Dupilumab, RPT193, Apremilast, EDP1815, ADX-914, AMG 451, Rocatinlimab, BMS-986166, AK120, ruxolitinib cream, MEDI3506, Upadacitinib, Tofacitinib ointment, and others
• Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
• Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers

Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Atopic Dermatitis Report Introduction
2. Atopic Dermatitis Executive Summary
3. Atopic Dermatitis Overview
4. Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment
5. Atopic Dermatitis Pipeline Therapeutics
6. Atopic Dermatitis Late Stage Products (Phase II/III)
7. Atopic Dermatitis Mid Stage Products (Phase II)
8. Atopic Dermatitis Early Stage Products (Phase I)
9. Atopic Dermatitis Preclinical Stage Products
10. Atopic Dermatitis Therapeutics Assessment
11. Atopic Dermatitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Atopic Dermatitis Key Companies
14. Atopic Dermatitis Key Products
15. Atopic Dermatitis Unmet Needs
16 . Atopic Dermatitis Market Drivers and Barriers
17. Atopic Dermatitis Future Perspectives and Conclusion
18. Atopic Dermatitis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Atopic Dermatitis Market https://www.delveinsight.com/report-store/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atopic Dermatitis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Atopic Dermatitis Epidemiology https://www.delveinsight.com/report-store/atopic-dermatitis-ad-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atopic Dermatitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.